Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer

Krystal, Geoffrey W.; Alesi, Erin R.; Tatum, James L.

doi:10.1158/1535-7163.mct-12-0011

Cited by 16 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been suggested, that FDG-PET/CT could provide a favorable and useful visualization of the tumor changes induced by both chemotherapy and targeted therapy like the treatment regimen in this trial [6,7,24]. Our findings support this suggestion.…”

Section: Discussionsupporting

confidence: 86%

Early ¹⁸F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

Early ¹⁸F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Positron emission tomography (PET) with 18 F-fluorodeoxyglucose (FDG) has been widely adopted as a tool for evaluating metabolic activity in tumors. FDG PET is also increasingly performed to detect earlier tumor responses to anti-cancer therapies [ 7 ]. It can allow the measurement of tumor response even in the absence of anatomic changes.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review

2016

View full text Add to dashboard Cite

The PET Response Criteria in Solid Tumors (PERCIST) is a new method for the quantitative assessment of metabolic changes in solid tumors. The assessments of tumor response between the RECIST and PERCIST have shown considerable difference in several studies. This pooled study was conducted to compare tumor response according to the two criteria in patients with solid tumors. We surveyed MEDLINE, EMBASE and PUBMED for articles with terms of the RECIST or PERCIST from 2009 and January 2016. There were six articles comparing the RECIST and PERCIST. A total of 268 patients were recruited; 81 with colorectal cancer, 60 with lung cancer, 48 with esophageal cancer, 28 with breast cancer, 14 with basal cell carcinoma, 12 with stomach cancer, 10 with head and neck cancer, and 16 with other rare cancers. The agreement of tumor response between the RECIST and PERCIST was moderate (k = 0.590). Of 268 patients, 101 (37.7%) showed discordance in the tumor responses between two criteria. When adopting the PERCIST, tumor response was upgraded in 85 patients and downgraded in 16. The estimated overall response rates were significantly different between two criteria (35.1% by RECIST vs. 54.1% by PERCIST, P < 0.0001). In conclusion, this pooled analysis demonstrates that the concordance of tumor responses between the RECIST and PERCIST criteria is not excellent. The PERCIST might be more suitable for assessing tumor response than the RECIST criteria.

show abstract

“…The RECIST 1.1 includes PET scans for the detection of new lesions. 18F-FDG PET is also increasingly adopted to monitor tumor responses to targeted therapies in solid tumor ( 24 ). It has been correlated with anatomical response and survival in patients treated with targeted agents for solid tumors ( 25 , 26 ).…”

Section: Discussionmentioning

confidence: 99%

Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer

Jung¹,

Kim²,

Kim³

et al. 2016

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Background: The criterion of two target lesions per organ in the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 is an arbitrary one, being supported by no objective evidence. The optimal number of target lesions per organ still needs to be investigated. We compared tumor responses using the RECIST 1.1 (measuring two target lesions per organ) and modified RECIST 1.1 (measuring the single largest lesion in each organ) in patients with small cell lung cancer (SCLC). Methods: We reviewed medical records of patients with SCLC who received first-line treatment between January 2004 and December 2014 and compared tumor responses according to the two criteria using computed tomography. Results: There were a total of 34 patients who had at least two target lesions in any organ according to the RECIST 1.1 during the study period. The differences in the percentage changes of the sum of tumor measurements between RECIST 1.1 and modified RECIST 1.1 were all within 13%. Seven patients showed complete response and fourteen showed partial response according to the RECIST 1.1. The overall response rate was 61.8%. When assessing with the modified RECIST 1.1 instead of the RECIST 1.1, tumor responses showed perfect concordance between the two criteria (k=1.0). Conclusions: The modified RECIST 1.1 showed perfect agreement with the original RECIST 1.1 in the assessment of tumor response of SCLC. Our result suggests that it may be enough to measure the single largest target lesion per organ for evaluating tumor response.

show abstract

Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer

Cited by 16 publications

References 20 publications

Early ¹⁸F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Early ¹⁸F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review

Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer

Contact Info

Product

Resources

About

Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer

Cited by 16 publications

References 20 publications

Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review

Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer

Contact Info

Product

Resources

About

Early ¹⁸F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Early ¹⁸F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab